NCT04270370View on ClinicalTrials.gov

A Study of LY3478045 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 16, 2020

Primary Completion Date

June 23, 2021

Study Completion Date

June 23, 2021

Conditions
Healthy
Interventions
DRUG

LY3478045

Administered orally.

DRUG

Placebo

Administered orally.

DRUG

Atorvastatin

Administered orally.

Trial Locations (1)

75247

Covance Dallas, Dallas

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04270370 - A Study of LY3478045 in Healthy Participants | Biotech Hunter | Biotech Hunter